about
Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral OncologyOral complications in hematopoietic stem cell recipients: the role of inflammationRetrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project DatabaThe Czech National Diamond-Blackfan Anemia Registry: clinical data and ribosomal protein mutations update.Serum citrulline levels as a marker of enterocyte function in patients after allogeneic hematopoietic stem cells transplantation - a pilot studyAntimicrobial chlorhexidine/silver sulfadiazine-coated central venous catheters versus those uncoated in patients undergoing allogeneic stem cell transplantation.The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT--results of a randomized multicentre study.Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database.Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients - worldwide battlefield.Oropharyngeal mucositis pain treatment with transdermal buprenorphine in patients after allogeneic stem cell transplantation.The availability of HEPA-filtered rooms and the incidence of pneumonia in patients after haematopoietic stem cell transplantation (HSCT): results from a prospective, multicentre, eastern European study.Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2.The impact of oral cryotherapy and oral and gastrointestinal mucositis after autologous stem cell transplantation.Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.The translocation t(2;11)(p21;q23) without MLL gene rearrangement--a possible marker of good prognosis in myelodysplastic syndrome patients.Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases.Allogeneic BMT in patients above 45 years of age: a single center experienceThe risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantationOral cavity care in patients after high-dose chemotherapy and stem cell transplantation: the East Forum EBMT Nurses Group standard of careOral cryotherapy can significantly reduce oral mucositis but not acute GVHD incidence in Flu/Mel conditioning allo-SCTAllogeneic stem cell transplantation can improve outcome of AML patients without complete cytogenetic response after induction and consolidation treatmentRole of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry
P50
Q27026718-C5D5FEE2-A1ED-4E39-9E93-8ACA67F7A153Q27027650-F4463865-341B-4249-8EA8-59AD4538443DQ30649483-C387CC94-EE9C-4CD0-8457-A162133CFD7DQ34180727-DBA7CCAE-A038-4AF7-99B3-A425E49FB39BQ36773720-7F80AE68-31F9-40F9-9B21-CADF36742133Q40420249-0646B679-2D71-4F61-A7E5-31A15B73BEE7Q40511917-130A3EDC-1F20-4F69-A225-D880FC136553Q41465999-D4B023CF-F70D-49C7-86AE-0E53D739E835Q41578847-049B162A-B272-4550-99B2-397210D1737EQ43032049-E43F414F-306A-4882-BFE8-206B47F939FDQ44983442-40C1D8C0-FE96-45DE-9814-E0F06D0350DAQ46059347-9C2D648A-9254-4ADE-9F77-E33D1F40A82FQ46132669-B71C84FD-BE0C-4DC1-9CBE-B2788E0AF20BQ46334893-4F9E6A14-3BD5-4B7F-861F-FCE3688979FEQ46758755-F59AE500-DDA5-403C-9874-840E9001425EQ47769358-9A334713-A58C-4D27-B93D-7D19C01F6A6CQ47905658-D6DD7F67-2571-4896-A9DE-1BD6B95FC67CQ48274743-59977898-A2B8-4136-A1CD-0BC45C38BF7BQ53086642-1228C3BD-00C0-4B0D-896E-50BE65A2C526Q73896937-E51F17A6-424B-44B3-90AB-0CC96CB32608Q83395298-6B282670-6919-4931-AED0-4E5590EABCFDQ83493107-797AC65C-D8CB-410E-A9D2-33B49D31CD95Q84589664-92FB36F8-B392-443E-A367-7387A9D750E9Q86483058-C34E34D9-B732-4253-A349-6EB3EA67961FQ89228728-E3A2EF4A-AFE8-4E09-82A1-0D88289E0AD7
P50
description
onkolog, hematolog
@cs
researcher ORCID ID = 0000-0002-9556-1796
@en
wetenschapper
@nl
name
Samuel Vokurka
@ast
Samuel Vokurka
@cs
Samuel Vokurka
@en
Samuel Vokurka
@es
Samuel Vokurka
@nl
type
label
Samuel Vokurka
@ast
Samuel Vokurka
@cs
Samuel Vokurka
@en
Samuel Vokurka
@es
Samuel Vokurka
@nl
prefLabel
Samuel Vokurka
@ast
Samuel Vokurka
@cs
Samuel Vokurka
@en
Samuel Vokurka
@es
Samuel Vokurka
@nl
P106
P214
P1153
8521929300
P21
P214
P31
P496
0000-0002-9556-1796
P569
1972-02-06T00:00:00Z
P691
mzk2005309233
P735
P7859
viaf-84643809